The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 10, 2007, Pages 1181-1191

  Lo Iacono, O ^a,b   Venezia, G ^a   Petta, S ^a   Mineo, C ^a   De Lisi, S ^a   Di Marco, V ^a   Rodolico, V ^a   Amato, M ^a   Ferraro, D ^a   Giordano, C ^a   Almasio, P L ^a   Craxi A ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANTIVIRUS AGENT; INSULIN; LEPTIN; PEGINTERFERON ALPHA2A; RESISTIN; RIBAVIRIN;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; FATTY LIVER; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER FIBROSIS; MALE; MULTIVARIATE ANALYSIS; OBESITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADIPOCYTES; ADULT; ANTIVIRAL AGENTS; FATTY LIVER; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; INTERFERON ALFA-2A; INTRA-ABDOMINAL FAT; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OBESITY; RIBAVIRIN;

EID: 34247539146     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03309.x     Document Type: Article

References (58)

1. Lonardo A, Adinolfi LE, Loria P, et al. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004 126 : 586 97.
2. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001 33 : 1358 64.
3. Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003 38 : 75 85.
4. Kumar D, Farrell GC, Fung C, et al. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002 36 : 1266 72.
5. Rubbia-Brandt L, Giostra E, Mentha G, et al. Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon. J Hepatol 2001 35 : 307.
6. Serfaty L, Andreani T, Giral P, et al. Virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001 34 : 428 34.
7. Perlemuter G, Sabile A, Letteron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002 16 : 185 94.
8. Rubbia-Brandt L, Fabris P, Paganin S, et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004 53 : 406 12.
9. Marchesini G, Forlani G, Bugianesi E. Is liver disease a treat to patients with metabolic disorders? Ann Med 2005 37 : 333 46.
10. Monto A, Alonzo J, Watson JJ, et al. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002 36 : 729 36.
11. Camma C, Bruno S, Di Marco V, et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 2006 43 : 64 71.
12. Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005 100 : 1509 15.
13. Fartoux L, Poujol-Robert A, Guechot J, et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005 54 : 1003 8.
14. Zekry A, McHutchison JG, Diehl AM. Insulin resistance and steatosis in hepatitis C virus infection. Gut 2005 54 : 903 6.
15. Muzzi A, Leandro G, Rubbia-Brandt L, et al. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 2005 42 : 41 6.
16. Perumalswami P, Kleiner DE, Lutchman G, et al. Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology 2006 43 : 780 7.
17. Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004 165 : 1499 508.
18. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004 126 : 840 8.
19. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003 125 : 1695 704.
20. Harrison SA. Correlation between insulin resistance and hepatitis C viral load. Hepatology 2006 43 : 1168 9.
21. Asselah T, Rubbia-Brandt L, Marcellin P, et al. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006 55 : 123 30.
22. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004 89 : 2548 56.
23. Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol 2006 101 : 2629 40.
24. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Educational Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001 285 : 2486 97.
25. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994 20 : 15 20.
26. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999 94 : 2467 74.
27. Strader DB, Wright T, Thomas DL, et al. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004 39 : 1147 71.
28. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from plasma fasting glucose and insulin concentrations in man. Diabetologia 1985 28 : 412 9.
29. Caro JF. Insulin resistance in obese and non-obese man. J Clin Endocrinol Metab 1991 73 : 691 5.
30. Zografos TA, Rigopoulou EI, Liaskos C, et al. Alterations of leptin during IFN-alpha therapy in patients with chronic viral hepatitis. J Hepatol 2006 44 : 848 55.
31. Stranges S, Dorn JM, Muti P, et al. Body fat distribution, relative weight, and liver enzyme levels: a population-based study. Hepatology 2004 39 : 754 63.
32. Fartoux L, Chazouilleres O, Wendum D, et al. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 2005 41 : 82 7.
33. Sanyal AJ. Review article: non-alcoholic fatty liver disease and hepatitis C - risk factors and clinical implications. Aliment Pharmacol Ther 2005 22 : 48 51.
34. Leandro G, Mangia A, Hui J, et al. HCV Meta-Analysis (on) Individual Patients' Data Study Group. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006 130 : 1636 42.
35. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004 114 : 147 52.
36. Fain JN, Madan AK, Hiler ML, et al. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004 145 : 2273 82.
37. Rasmussen MS, Lihn AS, Pedersen SB, et al. Adiponectin receptors in human adipose tissue: effects of obesity, weight loss, and fat depots. Obes Res 2006 14 : 28 35.
38. Trayhurn P. Endocrine and signalling role of adipose tissue: new perspectives on fat. Acta Physiol Scand 2005 184 : 285 93.
39. Gimeno RE, Klaman LD. Adipose tissue as an active endocrine organ: recent advances. Curr Opin Pharmacol 2005 5 : 122 8.
40. Vettor R, Milan G, Rossato M, et al. Review article: adipocytokines and insulin resistance. Aliment Pharmacol Ther 2005 22 (Suppl. 2 3 10.
41. Jonsson JR, Moschen AR, Hickman IJ, et al. Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol 2005 43 : 929 36.
42. Wang A, Hickman I, Richards A, et al. High molecular weight adiponectin correlates with insulin sensitivity with hepatitis C genotype 3, but not genotype 1 infection. Am J Gastroenterol 2005 100 : 2717 23.
43. Schaffler A, Scholmerich A, Buchler C. Mechanism of disease: adipocytokines and visceral adipose tissue- emerging role in non-alcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2005 6 : 273 80.
44. Tobe K, Oguta T, Tsukamoto C, et al. Relationship between serum leptin and fatty liver in Japanese male adolescent universitary students. Am J Gastroenterol 1999 94 : 3328 35.
45. Romero-Gomez M, Castellano-Megias VM, Grande L, et al. Serum leptin correlate with hepatic steatosis in chronic hepatitis C. Am J Gastroenterol 2003 98 : 1135 41.
46. Poordad FF. The role of leptin in NAFLD: contender or pretender? J Clin Gastroenterol 2004 38 : 841 3.
47. Marra F. Leptin and liver fibrosis: a matter of fat. Gastroenterology 2002 122 : 1529 32.
48. Petit JM, Minello A, Jooste V, et al. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J Clin Endocrinol Metab 2005 90 : 2240 3.
49. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev 2005 6 : 13 21.
50. Ding X, Saxena N, Lin S, et al. The role of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol 2005 166 : 1655 69.
51. Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin adiponectin and resistin. Clin Chem 2004 50 : 1511 25.
52. Hadziyannis SJ, Sette Jr. H, Morgan TR, et al. Peginterferon-alpha2a and Ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 55.
53. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus Ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 65.
54. Mello V, Cruz T, Nunez G, Simoes MT, et al. Peripheral insulin resistance during treatment of chronic hepatitis C with peguilated interferon plus ribavirin. J Med Virol 2006 78 : 1406 10.
55. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005 128 : 636 41.
56. Tai TY, Lu JY, Chen CL, et al. Interferon-alpha reduces insulin resistance and beta-cell secretion in responders among patients with chronic hepatitis B and C. J Endocrinol 2003 178 : 457 65.
57. Lu JY, Chuang LM, Yang WS, et al. Adiponectin levels among patients with chronic hepatitis B and C infections and in response to IFN-alpha therapy. Liver Int 2005 25 : 752 9.
58. Walsh MJ, Jonsson JR, Richardson MM, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006 55 : 529 35.